The liver is the most frequent site of CRC metastasis, and 79% of CRC liver metastases express EGFR (vs. 38% non-metastatic CRC); strategies targeting EGFR are central to the treatment of liver metastatic disease (Figure 2). This evidence concerns the gene EGFR and colorectal carcinoma.